All In Biotech

Drug Trial Radar · NCT05066672

Phase 2 Study of NV-5138 in Adults With Treatment Resistant Depression

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NV-5138 in Adults With Treatment Resistant Depression

Last checked: Nov 19, 2026Latest source record: Apr 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 250 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

250

Actual

Start

Jan 18, 2022

Primary completion

Jan 21, 2025

Study completion Jan 21, 2025

Sponsor

Lead sponsor
Navitor Pharmaceuticals, Inc.Industry
Sponsor type
Industry
Collaborators
Supernus Pharmaceuticals, Inc.
First posted
Oct 4, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the efficacy and safety of NV-5138 in adults with TRD

Conditions

  • Treatment Resistant Depression

Interventions

  • NV-5138Drug

    NV-5138 is a novel, orally bioavailable, selective, direct enhancer of mTORC1 cellular signaling

  • matched placeboDrug

    matched placebo oral capsules

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline to Week 4 in the Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score.Time frame: Baseline to Week 4

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Northwest Clinical Research Center, Inc.

    Bellevue, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.